富士製薬工業(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4554/E00975 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2021/01/15 | 日証協 | 126,954株 | -19.17% | 89,100株 | -43.65% | 262,668株 | -10.13% | 5,600株 | -84.7% |
2021/01/08 | 日証協 | 157,054株 | -1.53% | 158,132株 | +72.26% | 292,268株 | +6.06% | 36,602株 | +415.52% |
2020/12/30 | 日証協 | 159,500株 | +3.1% | 91,800株 | -40.34% | 275,571株 | -9% | 7,100株 | -85.77% |
2020/12/25 | 日証協 | 154,700株 | +31.77% | 153,883株 | -17.34% | 302,827株 | +21.19% | 49,900株 | +30.97% |
2020/12/18 | 日証協 | 117,400株 | +8% | 186,169株 | +44.62% | 249,871株 | -4.76% | 38,100株 | +7.02% |
2020/12/11 | 日証協 | 108,700株 | -9.27% | 128,730株 | +24.22% | 262,371株 | +4.13% | 35,602株 | -67.87% |
2020/12/04 | 日証協 | 119,800株 | +25.97% | 103,631株 | +80.23% | 251,969株 | +45.93% | 110,800株 | +628.95% |
2020/11/27 | 日証協 | 95,100株 | -7.76% | 57,500株 | -39.09% | 172,669株 | -5.78% | 15,200株 | -50.49% |
2020/11/20 | 日証協 | 103,100株 | +38.39% | 94,400株 | +88.8% | 183,269株 | +11.03% | 30,700株 | +65.05% |
2020/11/13 | 日証協 | 74,500株 | -40.3% | 50,000株 | -45.7% | 165,069株 | -27.02% | 18,600株 | -27.91% |
2020/11/06 | 日証協 | 124,800株 | +1.05% | 92,080株 | -20.74% | 226,169株 | +3.05% | 25,800株 | -4.44% |
2020/10/30 | 日証協 | 123,504株 | +42.12% | 116,174株 | +28.02% | 219,469株 | +4.67% | 27,000株 | -18.18% |
2020/10/23 | 日証協 | 86,900株 | +3.63% | 90,749株 | -11.2% | 209,669株 | +6.96% | 33,000株 | -17.3% |
2020/10/16 | 日証協 | 83,854株 | +56.29% | 102,200株 | +102.63% | 196,023株 | +23.5% | 39,901株 | -15.28% |
2020/10/09 | 日証協 | 53,654株 | +0.48% | 50,437株 | -22.76% | 158,718株 | -12.54% | 47,100株 | -48.43% |
2020/10/02 | 日証協 | 53,400株 | -22.63% | 65,300株 | +100.92% | 181,466株 | -4.08% | 91,330株 | +39.86% |
2020/09/25 | 日証協 | 69,019株 | -5.97% | 32,500株 | -55.41% | 189,185株 | +11.49% | 65,300株 | +44.47% |
2020/09/18 | 日証協 | 73,400株 | -36.56% | 72,885株 | -8.44% | 169,685株 | -78.51% | 45,200株 | -93.23% |
2020/09/11 | 日証協 | 115,700株 | +17.94% | 79,600株 | +975.68% | 789,485株 | +390.3% | 667,363株 | +6326.22% |
※株式分割は考慮していませんのでご注意ください。
Page Top